HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review.

AbstractPURPOSE: To conduct a systematic review and to evaluate the impact of postoperative adjuvant chemotherapy on the survival of patients with completely resected non-small cell lung cancer. METHODS: Relevant randomized trials and meta-analyses, published as articles or abstracts, were identified through electronic and hand searches by two reviewers. RESULTS: Seven meta-analyses and 26 randomized trials comparing surgery with or without chemotherapy met the pre-defined eligibility criteria for the review. The meta-analyses all showed a survival advantage for platinum- or UFT-based postoperative chemotherapy, although the results did not always achieve statistical significance. The results of individual trials were inconsistent, although recent trials have detected a large survival advantage with postoperative platinum-based chemotherapy. Differences in trial design, patient characteristics, disease stage, use of radiotherapy and chemotherapy regimen may explain the variation in results. CONCLUSIONS: Postoperative adjuvant platinum-based chemotherapy improves survival compared with surgery alone in completely resected non-small cell lung cancer. In patients fit for chemotherapy, the survival benefits strongly outweigh the adverse effects of the treatment.
AuthorsNaveed Alam, Gail Darling, William K Evans, Jean A Mackay, Frances A Shepherd, (Affiliation: Peter MacCallum Cancer Center, Melbourne, Australia.)
JournalCritical reviews in oncology/hematology (Crit Rev Oncol Hematol) Vol. 58 Issue 2 Pg. 146-55 (May 2006) ISSN: 1040-8428 [Print] Ireland
PMID16414266 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Cisplatin
  • Carboplatin
Topics
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Carboplatin (therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, pathology, surgery)
  • Chemotherapy, Adjuvant
  • Cisplatin (therapeutic use)
  • Humans
  • Lung Neoplasms (drug therapy, pathology, surgery)
  • Neoplasm Invasiveness
  • Practice Guidelines as Topic
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD